journal
MENU ▼
Read by QxMD icon Read
search

Expert Review of Neurotherapeutics

journal
https://www.readbyqxmd.com/read/28406336/intrajejunal-levodopa-infusion-therapy-for-parkinson-s-disease-practical-and-pragmatic-tips-for-successful-maintenance-of-therapy
#1
Nataliya Titova, K Ray Chaudhuri
Intrajejunal levodopa infusion (IJLI) therapy is one of the most influential therapies in moderate to late stage Parkinson's disease with documented effects on motor and non-motor symptoms and quality of life. The process of initiation and maintenance of therapy however, remains a challenge particularly in the long term. Areas covered: The authors reviewed "evidence base" for pathways and advice given to patients pre and post IJLI initiation. The authors found lack of patient, carer and clinician led "real life" advisory documents which need to be given to patients on IJLI...
April 13, 2017: Expert Review of Neurotherapeutics
https://www.readbyqxmd.com/read/28374628/birth-control-in-epilepsy-we-need-to-know-more
#2
Anne Davis, Alison Pack, Dale Hesdorffer, Page Pennell
No abstract text is available yet for this article.
April 10, 2017: Expert Review of Neurotherapeutics
https://www.readbyqxmd.com/read/28359202/response-to-birth-control-in-epilepsy-we-need-to-know-more
#3
Doodipala Samba Reddy
No abstract text is available yet for this article.
April 10, 2017: Expert Review of Neurotherapeutics
https://www.readbyqxmd.com/read/28343407/what-are-the-complications-and-emerging-strategies-for-preventing-depression-following-traumatic-brain-injury
#4
Melissa Jones, Laura Acion, Ricardo E Jorge
Depression is a common and disabling complication of traumatic brain injury (TBI). The high rates of post-TBI depression (PTBID) make this condition an important candidate for selective preventive interventions. Areas covered: The authors recently reported on the efficacy of sertraline, a selective serotonin reuptake inhibitor (SSRI), for the prevention of new cases of depression in the first six months after TBI. The authors review this and other studies on preventive strategies in PTBID as ascertained from a PubMed and citation search...
March 27, 2017: Expert Review of Neurotherapeutics
https://www.readbyqxmd.com/read/28335645/treatment-of-sleep-disorders-in-youth-with-adhd-what-is-the-evidence-from-randomised-controlled-trials-and-how-should-the-field-move-forward
#5
Samuele Cortese, Marco Angriman
No abstract text is available yet for this article.
March 24, 2017: Expert Review of Neurotherapeutics
https://www.readbyqxmd.com/read/28293960/moving-forward-how-depression-heterogeneity-hinders-progress-in-treatment-and-research
#6
E I Fried
No abstract text is available yet for this article.
March 22, 2017: Expert Review of Neurotherapeutics
https://www.readbyqxmd.com/read/28277802/oxycodone-extended-release-capsules-for-the-treatment-of-chronic-pain
#7
Sebastiano Mercadante
As a consequence of greater prescription opioid utilization, there has been the parallel increase in misuse, abuse, and overdose, which are serious risks. Associated new formulations may be safer. Areas covered: The introduction of abuse-deterrent opioid formulations and continuous programs to improve opioid prescribing practices may limit the opioid abuse and its consequences. Oxycodone extended release capsules are an extended-release (ER), microsphere-in-capsule abuse-deterrent-formulation designed to retain its extended-release properties following tampering or misuse (e...
March 10, 2017: Expert Review of Neurotherapeutics
https://www.readbyqxmd.com/read/28092989/therapeutic-complement-inhibition-a-promising-approach-for-treatment-of-neuroimmunological-diseases
#8
Kjara S Pilch, Peter J Spaeth, Nobuhiro Yuki, Benjamin R Wakerley
Autoimmunity is an important cause of disease both in the central and peripheral nervous systems. Aetiologies and clinical manifestations are complex and heterogeneous. Inappropriate control of complement activation at inappropriate sites has been recognized as a major determinant in several neurological conditions, including Guillain-Barré syndrome and neuromyelitis optica. In each case pathogenesis is thought to be associated with generation of autoantibodies which upon binding guide activation of the complement system to self-tissue...
March 6, 2017: Expert Review of Neurotherapeutics
https://www.readbyqxmd.com/read/28128002/ketamine-for-the-treatment-of-super-refractory-status-epilepticus-not-quite-yet
#9
Frederic Dorandeu
No abstract text is available yet for this article.
February 6, 2017: Expert Review of Neurotherapeutics
https://www.readbyqxmd.com/read/28132567/will-the-proteus-sensor-enhance-adherence-to-aripiprazole-or-other-antipsychotics
#10
Prakash Masand, Changsu Han, Chi-Un Pae
No abstract text is available yet for this article.
February 3, 2017: Expert Review of Neurotherapeutics
https://www.readbyqxmd.com/read/28132569/the-challenges-of-developing-a-gene-therapy-for-amyotrophic-lateral-sclerosis
#11
Muhibullah Sayed Tora, Orion Paul Keifer, Jason John Lamanna, Nicholas M Boulis
No abstract text is available yet for this article.
January 30, 2017: Expert Review of Neurotherapeutics
https://www.readbyqxmd.com/read/28092469/investigational-drugs-in-recent-clinical-trials-for-treatment-resistant-depression
#12
Ricardo P Garay, Carlos A Zarate, Thomas Charpeaud, Leslie Citrome, Christoph U Correll, Ahcène Hameg, Pierre-Michel Llorca
The authors describe the medications for treatment-resistant depression (TRD) in phase II/III of clinical development in the EU and USA and provide an opinion on how current treatment can be improved in the near future. Areas covered: Sixty-two trials were identified in US and EU clinical trial registries that included six investigational compounds in recent phase III development and 12 others in recent phase II clinical trials. Glutamatergic agents have been the focus of many studies. A single intravenous dose of the glutamatergic modulator ketamine produces a robust and rapid antidepressant effect in persons with TRD; this effect continues to remain significant for 1 week...
January 29, 2017: Expert Review of Neurotherapeutics
https://www.readbyqxmd.com/read/27927055/improving-the-therapeutic-efficacy-of-neural-progenitor-cell-transplantation-following-spinal-cord-injury
#13
Michael A Lane, Angelo C Lepore, Itzhak Fischer
There have been a wide range of preclinical studies testing cellular therapies to repair the injured spinal cord, yet they remain a challenge to translate because of inconsistencies in efficacy, limited number of patients with acute/subacute SCI and the high costs of clinical trials. Area covered: This paper focusses on the therapeutic potential of neural precursor cells (NPCs) because they can provide the cellular components capable of promoting repair and enhancing functional improvement following spinal cord injury (SCI)...
May 2017: Expert Review of Neurotherapeutics
https://www.readbyqxmd.com/read/27830959/neonatal-hypoxic-ischemic-encephalopathy-an-update-on-disease-pathogenesis-and-treatment
#14
Edibe Pembegül Yıldız, Barış Ekici, Burak Tatlı
Hypoxic ischemic encephalopathy (HIE) is the most important reason for morbidity and mortality in term-born infants. Understanding pathophysiology of the brain damage is essential for the early detection of patients with high risk for HIE and development of strategies for their treatments. Areas covered: This review discusses pathophysiology of the neonatal HIE and its treatment options, including hypothermia, melatonin, allopurinol, topiramate, erythropoietin, N-acetylcyctein, magnesium sulphate and xenon...
May 2017: Expert Review of Neurotherapeutics
https://www.readbyqxmd.com/read/28005435/is-there-a-weight-neutral-second-generation-antipsychotic-for-bipolar-disorder
#15
Fang Fang, Zuowei Wang, Renrong Wu, Joseph R Calabrese, Keming Gao
Antipsychotic-induced weight gain (WG) and metabolic abnormalities are major concerns. This review was untaken to answer if there is a weight-neutral second-generation antipsychotic for bipolar disorder (BPD). Areas covered: English-language literature in MEDLINE was searched with the keywords of antipsychotic/second-generation antipsychotic or generic/brand name of second-generation antipsychotic, and BPD/mania/depression or bipolar maintenance, and safety/tolerability or WG/weight increase, and randomized, placebo-controlled trial...
April 2017: Expert Review of Neurotherapeutics
https://www.readbyqxmd.com/read/28081625/an-unsound-aan-practice-advisory-on-poststroke-etanercept
#16
Ian A Clark
No abstract text is available yet for this article.
March 2017: Expert Review of Neurotherapeutics
https://www.readbyqxmd.com/read/28001435/how-should-physical-exercise-be-used-in-schizophrenia-treatment
#17
Alison R Yung, Joseph Firth
No abstract text is available yet for this article.
March 2017: Expert Review of Neurotherapeutics
https://www.readbyqxmd.com/read/27813429/clinical-utility-of-datscan%C3%A2-imaging-in-the-evaluation-of-patients-with-parkinsonism-a-us-perspective
#18
Stuart H Isaacson, Stanley Fisher, Fiona Gupta, Neal Hermanowicz, Daniel E Kremens, Mark F Lew, Kenneth Marek, Rajesh Pahwa, David S Russell, John Seibyl
Single photon emission computed tomography (SPECT) with Ioflupane I123 injection (DaTscan™) was approved by the Food and Drug Administration in 2011 for striatal dopamine transporter visualization to assist in the evaluation of adult patients with suspected parkinsonian syndromes. While brain SPECT imaging using DaTscan is a covered service under Medicare policy, there is a lack of consensus on its role in routine clinical practice in the US. Areas covered: To address this issue, an expert group of US-based movement disorders neurologists convened to discuss the clinical utility of DaTscan in movement disorders practices within the US...
March 2017: Expert Review of Neurotherapeutics
https://www.readbyqxmd.com/read/27690672/myasthenia-gravis-recent-advances-in-immunopathology-and-therapy
#19
John-Ih Lee, Sebastian Jander
Myasthenia gravis is the most frequent acquired disorder of neuromuscular transmission. In the majority of cases, pathogenic antibodies against components of the postsynaptic muscle endplate membrane can be detected. In recent years there have been significant advances in the pathophysiological understanding and therapy of the disease. Areas covered: PubMed searches were conducted for the term 'myasthenia gravis' cross-referenced with the terms 'immunology', 'subgroups', 'antibody', 'ocular', 'thymoma', 'treatment' and 'thymectomy'...
March 2017: Expert Review of Neurotherapeutics
https://www.readbyqxmd.com/read/27687685/treatment-of-epilepsy-in-patients-with-alzheimer-s-disease
#20
Filippo Sean Giorgi, Melania Guida, Andrea Vergallo, Ubaldo Bonuccelli, Gaetano Zaccara
Epilepsy is significantly more frequent in AD patients than in age-matched controls, even though the true extent of the phenomenon is not clear yet. Areas covered: In this review, we describe in detail the available data on the pharmacological treatment of epilepsy in patients with AD. We also briefly describe general principles of AEDs use in elderly, as well as the potential cognitive profile of AEDs and safety of concomitant psychotropic drugs in patients with epilepsy and AD. Expert commentary: As some preclinical data suggest a role of epileptiform discharges in cognitive decline in AD, a prompt diagnosis and treatment of seizures in these patients should be pursued...
March 2017: Expert Review of Neurotherapeutics
journal
journal
39882
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"